The Readout Loud
226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Our colleague Katie Palmer joins us to explain a burgeoning trend in pharmaceutical advertising that has health policy experts alarmed. We also discuss the White House's investment in biotech, a bellwether IPO, and the latest twist in the Merck-Seagen saga.